Radiolabeled Nanoparticles in Nuclear Oncology

Salvanou, Evangelia Alexandra; Bouziotis, Penelope; Tsoukalas, Charalampos

doi:10.21467/anr.1.1.38-55

Cited by 10 publications

(5 citation statements)

References 130 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the past decade, an increasing number of studies have been reported on tumor treatment with radiolabeled NPs, most of which have been performed with NPs radiolabeled with the β-emitting isotope Lutetium-177 ( 177 Lu, half-life: t 1/2 = 6.7 d) [12,[19][20][21][22][23][24]. Regarding 225 Ac, only a few studies have examined NPs radiolabeled with this radionuclide for tumor treatment [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225

et al. 2020

Self Cite

View full text Add to dashboard Cite

Actinium-225 (225Ac) is receiving increased attention for its application in targeted radionuclide therapy, due to the short range of its emitted alpha particles in conjunction with their high linear energy transfer, which lead to the eradication of tumor cells while sparing neighboring healthy tissue. The objective of our study was the evaluation of a gold nanoparticle radiolabeled with 225Ac as an injectable radiopharmaceutical form of brachytherapy for local radiation treatment of cancer. Au@TADOTAGA was radiolabeled with 225Ac at pH 5.6 (30 min at 70 °C), and in vitro stability was evaluated. In vitro cytotoxicity was assessed in U-87 MG cancer cells, and in vivo biodistribution was performed by intravenous and intratumoral administration of [225Ac]225Ac-Au@TADOTAGA in U-87 MG tumor-bearing mice. A preliminary study to assess therapeutic efficacy of the intratumorally-injected radio-nanomedicine was performed over a period of 22 days, while the necrotic effect on tumors was evaluated by a histopathology study. We have shown that [225Ac]225Ac-Au@TADOTAGA resulted in the retardation of tumor growth after its intratumoral injection in U87MG tumor-bearing mice, even though very low activities were injected per mouse. This gold nanoparticle radiopharmaceutical could be applied as an unconventional brachytherapy in injectable form for local radiation treatment of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…More recently, NPs have been investigated as nanobrachytherapy agents after intratumoral injection [ 8 , 9 , 10 , 11 , 12 ]. Among the various kinds of recently studied modifications of NPs is radiolabeling, which has been suggested for both diagnostic imaging and therapy of cancer [ 1 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

et al. 2022

Self Cite

View full text Add to dashboard Cite

Theranostic radioisotope pairs such as Gallium-68 (68Ga) for Positron Emission Tomography (PET) and Lutetium-177 (177Lu) for radioisotopic therapy, in conjunction with nanoparticles (NPs), are an emerging field in the treatment of cancer. The present work aims to demonstrate the ability of condensed colloidal nanocrystal clusters (co-CNCs) comprised of iron oxide nanoparticles, coated with alginic acid (MA) and stabilized by a layer of polyethylene glycol (MAPEG) to be directly radiolabeled with 68Ga and its therapeutic analog 177Lu. 68Ga/177Lu- MA and MAPEG were investigated for their in vitro stability. The biocompatibility of the non-radiolabeled nanoparticles, as well as the cytotoxicity of MA, MAPEG, and [177Lu]Lu-MAPEG were assessed on 4T1 cells. Finally, the ex vivo biodistribution of the 68Ga-labeled NPs as well as [177Lu]Lu-MAPEG was investigated in normal mice. Radiolabeling with both radioisotopes took place via a simple and direct labelling method without further purification. Hemocompatibility was verified for both NPs, while MTT studies demonstrated the non-cytotoxic profile of the nanocarriers and the dose-dependent toxicity for [177Lu]Lu-MAPEG. The radiolabeled nanoparticles mainly accumulated in RES organs. Based on our preliminary results, we conclude that MAPEG could be further investigated as a theranostic agent for PET diagnosis and therapy of cancer.

show abstract

“…They have been used for 125 I‐labeling of Fe@Fe 3 O 4 NPs (see Figure 4) (Su et al, 2015; J. Wang, Zhao, et al, 2016) after incorporating a tyrosine moiety for radioiodination. Replacing 125 I with 123 I/ 124 I, or 131 I could enable SPECT/MR, PET/MR, or radiotherapy, respectively (Salvanou, Bouziotis, & Tsoukalas, 2018).…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Radiolabeled metal‐based nanoparticles (MNPs) have drawn considerable attention in the fields of nuclear medicine and molecular imaging, drug delivery, and radiation therapy, given the fact that they can be potentially used as diagnostic imaging and/or therapeutic agents, or even as theranostic combinations. Here, we present a systematic review on recent advances in the design and synthesis of MNPs with major focuses on their radiolabeling strategies and the determinants of their in vivo pharmacokinetics, and together how their intended applications would be impacted. For clarification, we categorize all reported radiolabeling strategies for MNPs into indirect and direct approaches. While indirect labeling simply refers to the use of bifunctional chelators or prosthetic groups conjugated to MNPs for post‐synthesis labeling with radionuclides, we found that many practical direct labeling methodologies have been developed to incorporate radionuclides into the MNP core without using extra reagents, including chemisorption, radiochemical doping, hadronic bombardment, encapsulation, and isotope or cation exchange. From the perspective of practical use, a few relevant examples are presented and discussed in terms of their pros and cons. We further reviewed the determinants of in vivo pharmacokinetic parameters of MNPs, including factors influencing their in vivo absorption, distribution, metabolism, and elimination, and discussed the challenges and opportunities in the development of radiolabeled MNPs for in vivo biomedical applications. Taken together, we believe the cumulative advancement summarized in this review would provide a general guidance in the field for design and synthesis of radiolabeled MNPs towards practical realization of their much desired theranostic capabilities. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Radiolabeled Nanoparticles in Nuclear Oncology

Cited by 10 publications

References 130 publications

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Contact Info

Product

Resources

About